 Zacks Investment Research upgraded shares of PDS Biotechnology NASDAQ:PDSB from a sell rating to a hold rating in a research report released on Wednesday morning, Zacks.com reports. According to Zacks, PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, ... 